Lead Product(s): TCR based Natural Killer cells
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lion TCR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
The collaboration will initially focus on the development of TCR-NK products targeting Hepatitis B Virus (HBV) which is a leading cause of liver cancer and has a high unmet need for efficient treatment options.